Professor, Internal Medicine, University Kansas School of Medicine
Oncology
Dr. Stephen K. Williamson, MD
|
|
Give Review
Stephen K. Williamson works in the field of Oncology. He went to University of Kansas School of Medicine. He over the years received 7 awards: "Regional Top Doctor", "University of Kansas Top Doc Award", "Best Doctors in America", "Mother Teresa Award", "American Heart Association Award for Best Paper in Cardiology", "Best Paper in Internal Medicine" and "Super Doctor". Stephen Williamson is a published doctor and has 59 publications published. The lastest was: 'A pilot study of the physician acceptance of tele-oncology.'
Publications
- SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Perfo...
- Measurement of the Top Quark Pair ProDuction Cross Section in Proton-Proton Collisions at sqrt[s]=13  TeV.
- RalA signaling pathway as a therapeutic target in hepatocellular Carcinoma (HCC).
- Chemotherapy Outcomes by Histologic Subtypes of Non-Small-Cell Lung Cancer: Analysis of the Southwest Oncology Group Database for Antimicrotubule-Platinum Therapy.
- Predictive factors in patients with advanced and metastatic squamous cell Carcinoma of the head and neck: A study based on SWOG protocol S0420.
- Preclinical antitumor activity of a nanoparticulate SN38.
- Inhibition of RalA signaling pathway in treatment of non-small cell lung Cancer.
- Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell Carcinoma of the head and neck: Southwest Oncology ...
- Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell Lung can...
- Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal Cancer: results from North American Gastrointestinal Intergroup Tria...
- Phase II evaluation of sorafenib in advanced and metastatic squamous cell Carcinoma of the head and neck: Southwest Oncology Group Study S0420.
- Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for coloRectal carcinomatosis in vivo.
- Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung Cancer: a model for assessing population-related pharmacogenomics.
- Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung Cancer: SWOG 0222.
- Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal Cancer: N9741.
- Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal Cancer.
- Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell Carcinoma of the head and neck (SCCHN): a Southwest Oncol...
- Treatment of gastric Cancer.
- Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal Cancer: GI INT 0144.
- Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with ...
- Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal Cancer.
- Mutant DNA in plasma of lung Cancer patients: potential for monitoring response to therapy.
- A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic coloRectal can...
- Leiomyosarcoma of the inferior vena cava: a case report and review of the literature.
- Tirapazamine: a novel agent targeting hypoxic tumor Cells.
- Gemcitabine, irinotecan and celecoxib in patients with biliary Cancer.
- Impact of complete response to chemotherapy on overall survival in advanced colorectal Cancer: results from Intergroup N9741.
- Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung Cancer: results from Southwest Oncology Group randomized trials.
- Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung Cancer patients receiving platinum-based chemotherapy: SWOG Study...
- Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung Cancer: Southwest Oncology Group Trial S0003.
- Phase II trial of gemcitabine plus irinotecan in patients with esophageal Cancer: a Southwest Oncology Group (SWOG) trial.
- Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study.
- Phase II trial and cost Analysis of fazarabine in advanced non-small cell carcinoma of the lung: a Southwest Oncology Group study.
- Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenoCarcinoma of the stomach. A Southwest Oncology Group study.
- Docetaxel and ketoconazole in advanced hormone-refractory prostate Carcinoma: a phase I and pharmacokinetic study.
- A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal Cancer: a Southwest Oncology Grou...
- Phase II trial of piroxantrone in advanced non-small cell Carcinoma of the lung. A Southwest Oncology Group study.
- Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell Carcinoma of the head and neck: a ...
- Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung Cancer: a Southwest Oncology Group study.
- Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung Cancer. A Southwest Oncology Group study.
- Prolonged, alternating chemotherapy for extensive small cell lung Cancer. A Southwest oncology Group study.
- Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical Carcinoma: a ...
- Phase II evaluation of ifosfamide/mesna in metastatic prostate Cancer. A Southwest Oncology Group study.
- A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell Carcinoma of the head and ...
- Phase II evaluation of didemnin B in hormonally refractory metastatic prostate Cancer. A Southwest Oncology Group study.
- Treatment of small-cell lung Cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study.
- Phase I evaluation of spirogermanium and 5-fluorouracil in coloRectal carcinoma.
- Phase I trial of aggressive weekly chemotherapy in small-cell Carcinoma of the lung.
- Chemotherapy permits resection of metastatic colorectal Cancer: experience from Intergroup N9741.
- Evaluation of docetaxel in previously untreated extensive-stage small cell lung Cancer: a Southwest Oncology Group phase II trial.
- Treatment of non-small-cell lung Cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study.
- The new paradigm in the treatment of colorectal Cancer: are we hitting the right target?
- Activity of esorubicin in recurrent malignant Lymphoma: a Southwest Oncology Group study.
- Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung Cancer (S0004): a Southwest Oncology Group...
- A pilot study of the physician acceptance of tele-oncology.
- An evaluation of prostate-specific antigen as a screening test for prostate Cancer.
- Methotrexate cerebrospinal fluid pharmacokinetics in a patient with Lymphoma treated with methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexa...
- Clinical stage I testicular Cancer: orchiectomy without node dissection.
Schools
University of Kansas School of Medicine
University Okla Tulsa Med College
University Kans
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- University of Kansas Top Doc Award
- Best Doctors in America
- Mother Teresa Award
- American Heart Association Award for Best Paper in Cardiology
- Best Paper in Internal Medicine
- Super Doctor
Education
-
University of Kansas School of Medicine
Drug Facts
| NPI NUMBER | 1598859183 | |
| NPPES Provider LastName | WILLIAMSON | |
| NPPES Provider FirstName | STEPHEN | |
| NPPES Provider ZIPCode | 662052005 | |
| NPPES Provider State | KS | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 808.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 178.0 | |
| Percent Opioid Claims | 22.03 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1598859183 |
| Last Name Of The Provider | WILLIAMSON |
| First Name Of The Provider | STEPHEN |
| View All |
Similar Doctors
|
|
Dr. Takefumi Komiya, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joaquina C. Baranda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carol J. Fabian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joaquina C. Baranda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Prakash Neupane, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amy C. Rabe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allan R. Fleming, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Clay M. Anderson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. David W. Bouda, MD
This Doctor is OpenDoctor Recommended.
|